BackgroundThe optimal timing of resuming direct oral anticoagulants (DOACs) after high-risk endoscopic procedures remains uncertain. Existing recommendations are largely based on expert opinion, resulting in substantial practice variability. Understanding clinician equipoise and patient preferences is essential to inform the design of randomized trials, including the proposed Resumption of Direct Oral Anticoagulants After High-Risk Endoscopy (RESUME) trial.
Clinical equipoise and patient preferences for DOAC resumption after high-risk endoscopy: implications for a randomized trial
calendar_today
August 19, 2026
person
Smith, Z. L., Elmunzer, B. J., Forbes, N., Ruff, C. T., Hills, M. T., Scholtens, D. M.
domain
medrxiv